These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37694786)

  • 41. Nanosuspension development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin.
    Yang X; Miao X; Cao F; Li S; Ai N; Chang Q; Lee SMY; Zheng Y
    J Pharm Sci; 2014 Nov; 103(11):3576-3584. PubMed ID: 25187229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
    Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
    Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Practical method for preparing nanosuspension formulations for toxicology studies in the discovery stage: formulation optimization and in vitro/in vivo evaluation of nanosized poorly water-soluble compounds.
    Komasaka T; Fujimura H; Tagawa T; Sugiyama A; Kitano Y
    Chem Pharm Bull (Tokyo); 2014; 62(11):1073-82. PubMed ID: 25366311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY; Shah DA; Dave RH
    Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promising strategies for improving oral bioavailability of poor water-soluble drugs.
    Rocha B; de Morais LA; Viana MC; Carneiro G
    Expert Opin Drug Discov; 2023 Jun; 18(6):615-627. PubMed ID: 37157841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Challenges of nanoparticle albumin bound (nab™) technology: Comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension.
    Adick A; Hoheisel W; Schneid S; Mulac D; Azhdari S; Langer K
    Eur J Pharm Biopharm; 2023 Dec; 193():129-143. PubMed ID: 37918678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fabrication of Ibrutinib Nanosuspension by Quality by Design  Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
    Rangaraj N; Pailla SR; Chowta P; Sampathi S
    AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies.
    Du J; Li X; Zhao H; Zhou Y; Wang L; Tian S; Wang Y
    Int J Pharm; 2015 Nov; 495(2):738-49. PubMed ID: 26383838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation.
    Pınar SG; Canpınar H; Tan Ç; Çelebi N
    Eur J Pharm Sci; 2022 Apr; 171():106123. PubMed ID: 35017012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved Oral Bioavailability of Lacidipine Using Nanosuspension Technology: Inferior in vitro Dissolution and Superior in vivo Drug Absorption versus Lacipil®.
    Zhao J; Luo L; Fu Q; Guo B; Li Y; Geng Y; Wang J; Zhang T
    Curr Drug Deliv; 2016; 13(5):764-73. PubMed ID: 25963306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
    Alsofany JM; Hamza MY; Abdelbary AA
    AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
    Pouton CW
    Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement.
    Taneja S; Shilpi S; Khatri K
    Artif Cells Nanomed Biotechnol; 2016 May; 44(3):978-84. PubMed ID: 25724312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production, Characterization and Evaluation of Kaempferol Nanosuspension for Improving Oral Bioavailability.
    Qian YS; Ramamurthy S; Candasamy M; Shadab M; Kumar RH; Meka VS
    Curr Pharm Biotechnol; 2016; 17(6):549-55. PubMed ID: 26813303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
    Mohsin K; Alamri R; Ahmad A; Raish M; Alanazi FK; Hussain MD
    Int J Nanomedicine; 2016; 11():2829-38. PubMed ID: 27366063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
    Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
    Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs.
    Wang Y; Miao X; Sun L; Song J; Bi C; Yang X; Zheng Y
    Curr Pharm Des; 2014; 20(3):454-73. PubMed ID: 23651402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach.
    Mohapatra PK; Srivastava R; Varshney KK; Babu SH
    Anticancer Agents Med Chem; 2022; 22(10):1984-2001. PubMed ID: 34353274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.